On Tuesday, Biogen Inc (NASDAQ: BIIB) opened higher 0.66% from the last session, before settling in for the closing price of $141.71. Price fluctuations for BIIB have ranged from $128.51 to $238.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -5.94% over the last five years. Company’s average yearly earnings per share was noted -3.07% at the time writing. With a float of $145.61 million, this company’s outstanding shares have now reached $145.80 million.
The firm has a total of 7605 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.54%, operating margin of 31.0%, and the pretax margin is 20.12%.
Biogen Inc (BIIB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Biogen Inc is 0.52%, while institutional ownership is 91.01%. The most recent insider transaction that took place on Dec 09 ’24, was worth 17,293. In this transaction Head of Development of this company sold 110 shares at a rate of $157.21, taking the stock ownership to the 5,426 shares. Before that another transaction happened on Dec 09 ’24, when Company’s Officer proposed sale 110 for $157.21, making the entire transaction worth $17,293.
Biogen Inc (BIIB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.06% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Check out the current performance indicators for Biogen Inc (BIIB). In the past quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.25. Likewise, its price to free cash flow for the trailing twelve months is 7.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.18, a number that is poised to hit 3.56 in the next quarter and is forecasted to reach 15.86 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Analysing the last 5-days average volume posted by the [Biogen Inc, BIIB], we can find that recorded value of 1.85 million was better than the volume posted last year of 1.5 million. As of the previous 9 days, the stock’s Stochastic %D was 55.82%. Additionally, its Average True Range was 4.22.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 21.55%, which indicates a significant decrease from 72.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.52% in the past 14 days, which was higher than the 24.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $144.32, while its 200-day Moving Average is $185.46. Now, the first resistance to watch is $146.59. This is followed by the second major resistance level at $150.54. The third major resistance level sits at $153.07. If the price goes on to break the first support level at $140.11, it is likely to go to the next support level at $137.58. Now, if the price goes above the second support level, the third support stands at $133.63.
Biogen Inc (NASDAQ: BIIB) Key Stats
There are currently 146,375K shares outstanding in the company with a market cap of 20.88 billion. Presently, the company’s annual sales total 9,676 M according to its annual income of 1,632 M. Last quarter, the company’s sales amounted to 2,455 M and its income totaled 266,700 K.
